divendres, 18 de desembre del 2015

MassDevice.com +3 | The top 3 medtech stories for December 18, 2015

plus3-1x1

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.

 

3. PAD: Gore launches post-approval study of Viabahn stent graft

MassDevice.com news

W.L. Gore & Associates said it launched a post-approval study of its Viabahn stent graft for treating peripheral artery disease.

The 108-patient Reline Max study will examine the treatment of in-stent restenosis in the superficial femoral artery using the Viabahn device, which is designed to inhibit blood clots with its heparin coating. Read more


2. Titan Medical licenses Mayo Clinic IP for Sport robot-assisted surgery system

MassDevice.com news

Titan Medical said it licensed “know-how and certain technology” from Mayo Clinic for its Sport robot-assisted surgery platform.

The license covers intellectual property developed by Dr. David Larson, chairman of the colorectal surgery department at the Rochester, Minn.-based clinic, “including that developed through his participation in cadaver studies with Titan’s Sport surgical system,” Titan said. Read more


1. House passes spending bill, sending medical device tax pause to Senate

MassDevice.com news

The U.S. House of Representatives today overwhelmingly passed a $1.15 trillion spending bill, which would avoid another federal shutdown and lift the 40-year-old ban on U.S. crude oil exports.

The bipartisan, 316-113 vote sends the bill to the Senate, where Republican and Democratic leaders have agreed to combine it with a tax package passed yesterday that included a 2-year moratorium on the medical device tax. Read more

The post MassDevice.com +3 | The top 3 medtech stories for December 18, 2015 appeared first on MassDevice.



from MassDevice http://ift.tt/22eqiPf

Cap comentari:

Publica un comentari a l'entrada